The IBD SmartSelect Composite Rating for Travere Therapeutics rose from 94 to 96 Monday.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The upgrade means the stock is now outpacing 96% of all other stocks in terms of key performance metrics and technical strength. The best stocks tend to have a 95 or better grade as they launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Travere Therapeutics has now climbed above a proper buy zone after breaking out from a 19.08 buy point in a cup with handle.
One weak spot is the company's 72 EPS Rating, which tracks quarterly and annual earnings growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors, such as mutual funds and pension funds, over the last 13 weeks.
In Q2, the company posted 0% earnings-per-share growth. Sales growth climbed 111%, up from 98% in the prior quarter. The company has now posted accelerating growth in each of the last two quarters.
Travere Therapeutics holds the No. 8 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly-rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
